Making sorafenib irresistible: In vivo screening for mechanisms of therapy resistance in hepatocellular carcinoma hits on Mapk14

Hepatology

Volumn 61, Issue 5, 2015, Pages 1755-1757

  Avila, Matias ^a   Berasain, Carmen ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE KINASE; SHORT HAIRPIN RNA; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CANCER SCREENING; CANCER SURVIVAL; CELL CYCLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVATION; GENE SILENCING; GENE TARGETING; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THERAPY RESISTANCE; TRANSPOSON; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; FEMALE; GENETICS; HUMAN; LIVER NEOPLASMS, EXPERIMENTAL; MALE;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 14; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84928213235     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27739     Document Type: Article

References (8)

1. Berasain C. Hepatocellular carcinoma and sorafenib: too many resistance mechanisms? Gut 2013;62:1674-1675.
2. Rudalska R, Dauch D, Longerich T, McJunkin K, Wuestefeld T, Kang T-W, et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med 2014;20:1138-1146.
3. Sawey ET, Chanrion M, Cai C, Wu G, Zhang J, Zender L, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 2011;19:347-358.
4. Giannelli G, Rani B, Dituri F, Cao Y, Palasciano G. Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment. Gut 2014;63:1668-1676.
5. Uriarte I, Latasa MU, Carotti S, Fernández-Barrena MG, Garcia-Irigoyen O, Elizalde M, et al. Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development. Int J Cancer 2014; doi: 10.1002/ijc.29287.
6. Sakurai T, Kudo M, Umemura A, He G, Elsharkawy AM, Seki E, et al. p38α inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species. Cancer Res 2013;73:215-224.
7. Calvisi DF, Ladu S, Conner EA, Seo D, Hsieh J-T, Factor VM, et al. Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol 2011;54:311-319.
8. Galmiche A, Chauffert B, Barbare J-C. New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma. Cancer Lett 2014;346:159-162.